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Abstract
Background Time of diagnosis (TOD) of benign esophageal perforation is regarded as an important risk factor for clini-
cal outcome, although convincing evidence is lacking. The aim of this study is to assess whether time between onset of 
perforation and diagnosis is associated with clinical outcome in patients with iatrogenic esophageal perforation (IEP) and 
Boerhaave’s syndrome (BS).
Methods We searched MEDLINE, Embase and Cochrane library through June 2018 to identify studies. Authors were invited 
to share individual patient data and a meta-analysis was performed (PROSPERO: CRD42018093473). Patients were subdi-
vided in early (≤ 24 h) and late (> 24 h) TOD and compared with mixed effects multivariable analysis while adjusting age, 
gender, location of perforation, initial treatment and center. Primary outcome was overall mortality. Secondary outcomes 
were length of hospital stay, re-interventions and ICU admission.
Results Our meta-analysis included IPD of 25 studies including 576 patients with IEP and 384 with BS. In IEP, early TOD 
was not associated with overall mortality (8% vs. 13%, OR 2.1, 95% CI 0.8–5.1), but was associated with a 23% decrease 
in ICU admissions (46% vs. 69%, OR 3.0, 95% CI 1.2–7.2), a 22% decrease in re-interventions (23% vs. 45%, OR 2.8, 95% 
CI 1.2–6.7) and a 36% decrease in length of hospital stay (14 vs. 22 days, p < 0.001), compared with late TOD. In BS, no 
associations between TOD and outcomes were found. When combining IEP and BS, early TOD was associated with a 6% 
decrease in overall mortality (10% vs. 16%, OR 2.1, 95% CI 1.1–3.9), a 19% decrease in re-interventions (26% vs. 45%, OR 
1.9, 95% CI 1.1–3.2) and a 35% decrease in mean length of hospital stay (16 vs. 22 days, p = 0.001), compared with late TOD.
Conclusions This individual patient data meta-analysis confirms the general opinion that an early (≤ 24 h) compared to a 
late diagnosis (> 24 h) in benign esophageal perforations, particularly in IEP, is associated with improved clinical outcome.
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Esophageal perforation is characterized by transmural dis-
ruption of the esophagus that could lead to contamination 
of the surrounding tissue. The majority of underlying causes 
consists of iatrogenic esophageal perforations (IEP) and 
spontaneous esophageal perforations, also known as Boer-
haave’s syndrome (BS) [1]. The incidence of IEP is rising 
due to the increase in invasive endoscopic esophageal inter-
ventions in clinical practice [2–4].
Initial management of esophageal perforation generally 
consists of either surgical or endoscopic treatment (includ-
ing drainage) combined with fasting, enteral tube feeding 
and intravenous antibiotics. Patients with either IEP or BS 
are usually managed with similar therapeutic strategies [5]. 
Nonetheless, optimal treatment selection for individual 
patients with esophageal perforation remains a challenge in 
current practice and is largely based on expert opinion as 
supportive high-level confidence evidence from comparative 
studies is generally lacking. Despite a reduction in mortality 
rates during the past decades, esophageal perforation con-
tinues to be associated with severe adverse clinical outcome 
[6]. A pooled meta-analysis published in 2013 showed a 
mortality rate of 12% [7], while a nation-wide population-
based study in England reported a 35% overall mortality 
rate in patients diagnosed with predominantly BS between 
2010 and 2012 [6]. The latter study also identified older age, 
type of therapeutic management (i.e., endoscopy) and lower 
patient volume per hospital as risk factors for a worse out-
come in patients with esophageal perforation. Furthermore, 
BS was associated with a higher overall mortality rate when 
compared with IEP. This may be related to the higher risk of 
diagnostic delay as a result of the out-of-hospital setting in 
which BS often occurs.
When exploring the nature of clinical presentation, 
numerous case series have investigated whether time 
between onset and diagnosis is associated with clinical out-
comes in patients with esophageal perforation [5, 8–13]. As 
a result, authors of some studies have suggested that diag-
nosis within 24 h, the so-called ‘golden 24 h-rule’, is asso-
ciated with improved outcome in patients with any type of 
esophageal perforation [5, 9, 13]. However, given the design, 
heterogeneity in types of perforation and relatively small 
sample size of these studies, no convincing evidence for an 
association between time of diagnosis of esophageal perfora-
tion and clinical outcome has been found.
In an effort to pool results from published case series, 
we performed an individual patient data meta-analysis 
(IPDMA). This study design allows to combine raw patient 
data from case series and to stratify outcomes by type of 
perforation, while correcting for confounders in a multivari-
able analysis [14]. Our aim was to assess whether time of 
diagnosis (TOD) was associated with clinical outcomes in 
patients with IEP and BS.
Patients and methods
The study protocol (PROSPERO: CRD42018093473) for the 
IPDMA was designed by the core members (B.V., C.R., P.S.) 
and approved by all collaborating authors of the Esopha-
geal Perforation Study Group. The PRISMA guidelines for 
IPDMA and the MINORS critical appraisal tool for non-
randomized interventional studies were followed [15, 16].
Search strategy and study selection
A systematic literature search was performed in the elec-
tronic databases MEDLINE, EMBASE and Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) until June 
30, 2017, which was updated until June 30, 2018 during the 
comprehensive process of inviting corresponding authors 
and data acquisition. Combinations of the following search 
terms with synonyms for “esophageal perforation”, “treat-
ment” and “clinical study” were used to identify relevant 
studies (Supplementary Table 2). Thereafter, two research-
ers (B.V. and B.L.) independently screened and selected 
all studies according to the per protocol defined inclusion 
criteria: (1) adult patients treated for IEP or BS; (2) study 
reported original data on clinical outcome; (3) publications 
in English, Dutch, German; and (4) study size of ≥ 5 patients 
with IEP and/or BS. Studies were excluded when: (1) study 
exclusively reported on other types of esophageal perfora-
tion (e.g., malignant, external traumatic or intra-operative); 
(2) no full-text version available; (3) outcome only published 
as congress abstract.
The systematic search identified 2332, 3627 and 7 records 
from the Medline, Embase and Cochrane databases, respec-
tively (Fig. 1). After removing duplicates, 4316 records 
remained, of which 4066 were excluded after screening the 
title and abstract. Subsequently, full-text assessment of the 
remaining 250 eligible articles resulted in 139 eligible stud-
ies. Reference cross-check of these studies yielded 3 addi-
tional eligible studies. Finally, a total of 142 studies were 
selected for inquiry of individual patient data (IPD).
Individual patient data acquisition and quality 
assessment
We invited the corresponding and senior authors of 
selected studies per e-mail to share individual data of only 
patients with IEP and BS (Supplementary Table 5). All 
studies of which IPD was shared for meta-analysis were 
critically appraised with the Methodological Index for 
Non-Randomized Studies (MINORS) tool [16]. As sup-
ported by the tool designers, we only used the first 8 items 
for quality assessment because our data set comprised only 
non-comparative observational studies (Supplementary 
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Table 4a). The items were scored as 0 (not reported), 1 
(reported but inadequate) or 2 (reported and adequate).
Study endpoints and definitions
We investigated whether TOD was associated with clinical 
outcomes in patients with IEP, and BS. TOD was defined 
as time between symptom onset and perforation diagnosis, 
measured in hours. We compared patients diagnosed ≤ 24 
vs. > 24 h after onset, as well as patients diagnosed ≤ 12 
vs. > 12 h after onset. We selected the 12- and 24-h thresh-
olds to demonstrate the clinical importance of diagnosing an 
esophageal perforation at an early stage of the perforation. 
The primary endpoint of the study was overall mortality 
(i.e., all-cause mortality during follow-up). Secondary end-
points were length of hospital stay, need for re-interventions 
and intensive care unit (ICU) admissions for management of 
esophageal perforation. In addition, we assessed differences 
in therapeutic management and clinical outcomes between 
IEP and BS.
Additional endpoints were whether TOD was associated 
with clinical outcomes in patients treated with surgical or 
endoscopic interventions. Furthermore, we assessed risk 
factors for overall mortality during follow-up of patients 
with IEP and BS. Risk factors assessed included age (< 70 
vs ≥ 70 years), gender, location of perforation and initial 
treatment (surgery, endoscopy, conservative or a combina-
tion of surgery and endoscopy).
Benign esophageal perforation was defined as a full-
thickness rupture of the esophageal wall, caused by either 
(1) IEP following a therapeutic (or diagnostic) endoscopic 
procedure; or (2) BS (i.e., spontaneous esophageal rupture). 
Location of perforation was subdivided in the proximal/tho-
racic (i.e., proximal and middle one-third) and distal/abdom-
inal (i.e., distal one-third) esophagus. Therapeutic approach 
was subdivided into surgical, endoscopic and conservative. 
Surgical approach was defined as any surgical intervention to 
treat the perforation (e.g., primary repair, video-assisted tho-
racic surgery with or without drain placement, esophagec-
tomy). Endoscopic approach was defined as any endoscopic 
intervention to close the perforation (e.g., stent placement, 
clip placement, endoscopic vacuum therapy). Conservative 
approach was defined as primary treatment with ≥ 1 of the 
following supportive treatments for management of esopha-
geal perforation: fasting (“nil by mouth”); enteral tube feed-
ing; oral or intravenous antibiotics; percutaneous thoracic 
drain placement. All other study definitions are listed in the 
supplementary files (Supplementary Table 3).
Statistical analysis
The model used for primary, secondary and additional end-
points used a meta-analytical effect estimate that was derived 
from the source data of all studies simultaneously. Patients 
with missing data on TOD were excluded from this analysis.
As advised by the PRISMA-IPD guidelines [15], we used 
a mixed effects model with random intercepts and slopes to 
account for clustering of patients within studies. We used a 
multivariable logistic regression model, introducing base-
line parameters that significantly differed (p-value < 0.2) in 
the univariable analysis. Multivariable logistic regression 
was performed with backward stepwise elimination until 
all remaining variables reached a p-value of < 0.05. Results 
were expressed as percentages, odds ratio (OR) with 95% 
CI and significance levels and depicted in forest plots. To 
test whether TOD was associated with log-transformed 
length of hospital stay, we used a linear mixed effects model, 
introducing baseline parameters that significantly differed 
(p-value < 0.2) in the univariable analysis and performed 
backward stepwise elimination until all remaining variables 
reached a p-value of < 0.05. Differences in length of hospital 
stay were expressed as percentages and significance levels.
Multivariable Cox regression analysis was performed to 
calculate overall mortality hazard ratios (HR) with 95% con-
fidence intervals (CI) while adjusting for the potential con-
founders age, gender, etiology, esophageal location of perfo-
ration and initial treatment modality. Difference in mortality 
between IEP and BS is shown with a Kaplan–Meier survival 
curve.
Differences in therapeutic management and clinical out-
comes between patients with IEP and BS were assessed 
with Chi-square and t tests for categorical and continuous 
data, respectively. Survival was calculated from the date 
of perforation diagnosis to the date of death, plotted using 
Kaplan–Meier curves and compared using a log-rank test.
A two-tailed p-value of < 0.05 was considered significant 
in all statistical analyses. SPSS version 25.0 (IBM Corp, 
IBM SPSS Statistics for Windows, Armonk, NY) was used 
for study analyses.
Results
Individual patient data collection
The systematic review yielded 142 studies that met the study 
selection criteria for IPD acquisition. The characteristics of 
all eligible studies can be found in the supplementary files 
(Supplementary Table 5). For 27 studies no contact informa-
tion was available. Therefore, authors of 115 studies were 
invited to share their IPD (Fig. 1).
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In total, the IPD was based on 25 studies that were pub-
lished between 2004 and 2017 (Supplementary Table 6). 
Authors of five cohorts included unpublished data of 58 
patients and confirmed that the additional data were col-
lected in accordance with the methodology of the original 
study [13, 17–20]. We found no inconsistencies between 
shared and published data. Supplementary Table 6 shows 
the study inclusion period and patient characteristics of all 
25 included databases.
Risk of bias assessment
We assessed the risk of bias in all 25 included studies (Sup-
plementary Table 4b). The mean MINORS score was 6.8 
(SD ± 1.7, range 3–10). All studies collected the data ret-
rospectively (item #3), except for one study that was based 
on prospective data collection [21]. None of the studies 
reported on observer (item #5) or sample size bias (item #8).
Baseline characteristics
In total, individual raw data of 960 patients with IEP 
(n = 576) and BS (n = 384) were included in the study. 
The baseline characteristics of all patients and differences 
between IEP and BS are shown in Table 1.
In patients with IEP, the mean age was 63 years (SD ± 18), 
333 (58%) were male and in 279 (49%) the perforation was 
located in the distal esophagus. After IEP diagnosis, initial 
therapeutic management consisted of surgery in 269 (47%) 
patients, endoscopy in 139 (24%), surgery and endoscopy 
in 30 (5%) and conservative treatment in 138 (24%). Fol-
lowing initial management, a total of 264 (57%) patients 
were admitted to the ICU and 143 (26%) required one or 
more re-interventions for perforation management. Median 
follow-up was 180 days (IQR 90–1521). A total of 55 (10%) 
patients died as a result of IEP. Median time to death was 
37 days (IQR 13–90).
In patients with BS, the mean age was 64 years (SD ± 17), 
284 (74%) were male and in 315 (83%) the perforation was 
located in the distal esophagus. After BS diagnosis, initial 
therapeutic management consisted of surgery in 232 (60%) 
patients, endoscopy in 52 (14%), surgery and endoscopy in 
43 (11%) and conservative treatment in 56 (15%). Follow-
ing initial management, a total of 267 (86%) patients were 
admitted to the ICU and 146 (40%) required one or more 
re-interventions for management of perforation. Median 
follow-up was 131 days (IQR 63–775). A total of 65 (17%) 
patients died as a result of BS. Median time to death was 
20 days (IQR 6–46).
Figure  2 shows survival differences during the first 
3 months after diagnosis between patients with IEP and 
BS. Cox regression analysis showed that, after adjustment 
for confounders, IEP was associated with decreased overall 
mortality when compared with BS (10% vs. 17%, HR 2.0, 
95% CI 1.3–3.1). Data were missing on TOD in 288 (30%) 
patients. Therefore, we included 672/960 (70%) patients 
for analysis of the primary and secondary endpoints. Dif-
ferences in age and initial treatment (surgery, endoscopy) 
between included and excluded patients were observed (Sup-
plementary Table 7). Table 2 shows differences between 
baseline characteristics and outcome for early and late TOD 
(12 h and 24 h) in patients with IEP and BS.
Time of diagnosis and clinical outcome of IEP
We assessed whether TOD was associated with clinical out-
comes in patients with IEP (Table 3 and Fig. 3). Analysis 
of primary outcome in the 24 h subgroup showed that early 
TOD was not associated with overall mortality compared 
with late TOD (8% vs. 13%, OR 2.1, 95% CI 0.8–5.1). 
Analysis of the 12 h subgroup showed a similar trend, with 
no association between early TOD and overall mortality 
Table 1  Baseline characteristics and unadjusted differences between 
patients with IEP and BS
Values represent number of patients (percentage of total in column) 
[n (%)], mean (SD), or median (IQR). Bold p-values indicate that dif-
ferences between the groups were statistically significant
n number of patients, SD standard deviation, IEP iatrogenic esopha-
geal perforation, BS Boerhaave’s syndrome, ICU intensive care unit, 
LOS length of hospital stay, TOD time of diagnosis, IQR interquartile 
range
Variables All patients IEP BS P value
(n = 960) (n = 576) (n = 384)
Age, years 
(mean ± SD)
64 (18) 63 (18) 64 (17) 0.320




 Proximal 362 (38) 296 (52) 66 (17)
 Distal 594 (62) 279 (49) 315 (83)
Initial treatment, n 
(%)
 Surgery 501 (52) 269 (47) 232 (60) < 0.001
 Endoscopy 191 (20) 139 (24) 52 (14) < 0.001
 Conservative only 194 (20) 138 (24) 56 (15) < 0.001
 Surgery and endos-
copy




120 (13) 55 (10) 65 (17) 0.001
 ICU admission, n 
(%)
531 (68) 264 (57) 267 (86) < 0.001
 Re-intervention, 
n (%)
289 (32) 143 (26) 146 (40) < 0.001
 LOS, median days 
(IQR)
18 [9–35] 15 [8–28] 27 [13–47] < 0.001
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compared with late TOD (7% vs. 12%, OR 2.2, 95% CI 
0.9–5.2).
Analysis of secondary outcomes in the 24  h sub-
group showed that early TOD was associated with a 23% 
decrease in ICU admissions (46% vs. 69%, OR 3.0, 95% CI 
1.2–7.2), a 22% decrease in need for re-interventions (23% 
vs. 45%, OR 2.8, 95% CI 1.2–6.7) and a 36% decrease in 
mean length of hospital stay 14 vs. 22 days, p < 0.001), 
compared with late TOD. Analysis of the 12  h sub-
group showed that early TOD was associated with a 21% 
decrease in ICU admissions (44% vs. 65%, OR 2.3, 95% CI 
1.1–4.8), a 25% decrease in need for re-interventions (21% 
vs. 46%, OR 2.8, 95% CI 1.3–5.7) and a 35% decrease in 
Fig. 2  Survival differences 
between patients with IEP and 
BS during 3 months of follow-
up. Hazard ratio is adjusted for 
age, gender, etiology, perfora-
tion location and initial treat-
ment strategy. IEP iatrogenic 
esophageal perforation, BS 
Boerhaave’s syndrome
Table 2  Unadjusted differences in baseline characteristics and clinical outcome between early and late TOD in patients with IEP and BS
Bold p-values indicate that differences between the groups were statistically significant
n number of patients, TOD time of diagnosis, h hour, SD standard deviation
Iatrogenic esophageal perforation (n = 411) p Boerhaave’s syndrome (n = 261) p
TOD:  ≤ 12 h  > 12 h  ≤ 24 h  > 24 h  ≤ 12 h  > 12 h  ≤ 24 h  > 24 h
Characteristics n = 257 n = 134 p n = 323 n = 88 n = 101 n = 149 p n = 149 n = 117
Age, mean years (± SD) 61 (18) 59 (18) 0.197 63 (19) 58 (16) 0.042 64 (18) 59 (15) 0.022 66 (17) 58 (16) < 0.001
Gender: male, n (%) 142 (55) 79 (59) 0.483 143 (44) 36 (41) 0.573 78 (77) 106 (71) 0.284 106 (74) 86 (74) 0.984
Location perforation, n (%) 0.232 0.057 < 0.001 < 0.001
 Proximal 141 (55) 65 (49) – 180 (56) 39 (44) – 4 (4) 29 (20) – 6 (4) 27 (23) –
 Distal 116 (45) 69 (51) – 143 (44) 49 (56) – 97 (96) 120 (81) – 138 (96) 90 (77) –
Initial treatment, n (%)
 Surgery 111 (43) 47 (35) 0.121 141 (44) 34 (39) 0.399 66 (65) 82 (55) 0.104 93 (65) 66 (56) 0.178
 Endoscopy 74 (29) 38 (28) 0.928 90 (28) 25 (28) 0.920 12 (12) 23 (15) 0.427 16 (11) 19 (16) 0.227
 Conservative only 64 (25) 35 (26) 0.793 76 (24) 23 (26) 0.612 9 (9) 29 (20) 0.023 14 (10) 24 (21) 0.014





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































mean length of hospital stay (13 vs. 20 days, p < 0.001), 
compared with late TOD.
Time of diagnosis and clinical outcome of BS
We also assessed whether TOD was associated with clinical 
outcomes in patients with BS (Table 3 and Fig. 3). Analysis 
of the 24 h subgroup showed that early TOD was not associ-
ated with overall mortality compared with late TOD (15% 
vs. 18%, OR 2.0, 95% CI 0.7–5.4). Analysis of the 12 h sub-
group showed that early TOD was also not associated with 
overall mortality compared with late TOD (12% vs. 18%, 
OR 2.4, 95% CI 0.8–7.2).
Analysis of secondary outcomes in the 24 h subgroup 
showed that early TOD was not associated with fewer ICU 
admissions (88% vs. 82%, OR 1.5, 95% CI 0.5–4.5), fewer 
re-interventions (33% vs. 46%, OR 1.9, 95% CI 0.98–3.6) 
or shorter length of hospital stay (25 vs. 23 days, p = 0.710), 
compared with late TOD. Analysis of the 12 h subgroup 
similarly showed that early TOD was not associated with 
fewer ICU admissions (90% vs. 82%, OR 0.9, 95% CI 
0.7–2.9), fewer re-interventions (37% vs. 42%, OR 1.2, 95% 
CI 0.7–2.3) or shorter length of hospital stay (24 vs. 25 days, 
p = 0.721), compared with late TOD.
Time of diagnosis and clinical outcome of IEP and BS
We assessed whether TOD was associated with clinical 
outcomes when combining results of IEP and BS in a mul-
tivariable analysis, with adjustment for type of perforation 
and other confounders (Table 3 and Fig. 3). Analysis of the 
24 h subgroup showed that early TOD was associated with 
a 6% decrease in overall mortality compared with late TOD 
(10% vs. 16%, OR 2.1, 95% CI 1.1–3.9). Analysis of the 12 h 
subgroup showed that early TOD was similarly associated 
with a 7% decrease in overall mortality compared with late 
TOD (8% vs. 15%, OR 2.1, 95% CI 1.1–4.0).
Analysis of the secondary outcomes in the 24 h subgroup 
showed that early TOD was associated with a 35% decrease 
in mean length of hospital stay (16 vs. 22 days, p = 0.001), 
a 19% decrease in need for re-interventions (26% vs. 45%, 
OR 1.9, 95% CI 1.1–3.2) and no difference in ICU admis-
sion (59% vs. 76%, OR 1.8, 95% CI 0.9–3.5) compared with 
late TOD. Analysis of the 12 h subgroup showed that early 
TOD was associated with a 28% decrease in mean length 
of hospital stay (14 vs. 22 days, p < 0.001), a 19% decrease 
in need for re-intervention (25% vs. 44%, OR 1.8, 95% CI 
1.1–2.9) and no difference in ICU admissions (57% vs. 74%, 
OR 1.6, 95% CI 0.9–3.0) compared with late TOD.
Table 4  Multi-level multivariable regression analysis comparing early vs. late time of diagnosis of benign esophageal perforation in patients 
treated with endoscopic intervention only or surgical interventions only
Bold p-values indicate that differences between the groups were statistically significant
Numbers of patients within 12 h interval do not always add up to the total number of patients owing to missing diagnostic interval data in 31 
(5%) patients with IEP and BS
n number of patients, TOD time of diagnosis, IEP iatrogenic esophageal perforation, BS Boerhaave’s syndrome, h hour, OR odds ratio, CI confi-
dence interval, ICU intensive care unit, LOS length of stay in the hospital (median), IQR interquartile range
*Analysis is adjusted for age, gender, location of perforation, etiology of benign esophageal perforation and center of treatment
Endoscopy TOD (12 h) Adjusted* TOD (24 h) Adjusted*








p OR 95%CI p
Outcome, n (%)
 Mortality 7 (8) 10 (16) 0.123 2.2 0.6–7.5 0.217 9 (9) 8 (18) 0.088 2.8 0.8–10.2 0.118
 ICU admission 30 (39) 42 (74)  < 0.001 6.8 2.3–19.7 0.001 40 (43) 32 (76)  < 0.001 4.6 1.5–13.7 0.007
 Re-intervention 26 (32) 35 (60) 0.001 4.6 1.8–11.8 0.002 33 (33) 29 (67)  < 0.001 4.7 1.8–12.3 0.002
 LOS, days [IQR] 11 [6–22] 26 [16–41]  < 0.001 – –  < 0.001 13 [7–22] 29 [17–42]  < 0.001 – –  < 0.001
Surgery TOD (12 h) Adjusted* TOD (24 h) Adjusted*








p OR 95%CI p
Outcome, n (%)
 Mortality 13 (7) 16 (12) 0.136 2.1 0.9–4.7 0.072 24 (10) 11 (11) 0.839 1.4 0.6–3.2 0.396
 ICU admission 104 (87) 101 (88) 0.920 0.8 0.3–2.2 0.667 51 (25) 41 (44) 0.001 0.8 0.3–2.3 0.637
 Re-intervention 38 (24) 52 (44)  < 0.001 2.2 1.2–4.1 0.011 125 (88) 80 (87) 0.808 1.8 0.9–3.6 0.072




We assessed whether TOD was associated with clinical 
outcomes in patients initially treated with surgical or endo-
scopic interventions. Results are shown in Table 4. In sum-
mary, we found no association between TOD and overall 
mortality in patients initially treated with a surgical or an 
endoscopic intervention.
Furthermore, we assessed risk factors associated with 
overall mortality in patients with IEP or BS. Results are 
shown in Table 5. Multivariable analysis identified age ≥ 70 
to be associated with overall higher mortality in patients 
with IEP and BS. In addition, surgery, endoscopic and con-
servative treatment were all significantly associated with 
overall higher mortality in patients with IEP.
Discussion
This IPDMA included 960 patients with esophageal perfora-
tion from 25 retrospective cohorts. Whereas in patients with 
IEP or BS, the association between TOD and mortality was 
found to be not statistically significant, combining the results 
of IEP and BS showed a reduced overall mortality within 
12 to 24 h after diagnosis. In addition, either separately or 
combined, early diagnosis of IEP and BS was associated 
with a reduction in ICU admissions, re-interventions and 
length of hospital stay.
Overall mortality in our IPDMA was 13% which corre-
sponds with the pooled mortality (11%) from the included 
but not having responded 117 eligible studies in the current 
systematic review (Supplementary Table 5). In line with 
this, this percentage reflects the pooled mortality (12%) 
reported in a conventional meta-analysis of 75 studies [7].
Our study provides an interesting insight into the exist-
ing literature on esophageal perforation. Previous studies 
predominantly consisted of uncontrolled, retrospective 
evaluations of esophageal perforation, irrespective of type 
of perforation. Approximately three-quarters of the 142 
studies yielded by our systematic literature review (Supple-
mentary Table 5), also included patients with malignant, 
external traumatic or intra-operative perforations. The fact 
that IEP, BS and the remaining types of perforation vary 
significantly makes the interpretation of study findings and 
translation to daily clinical practice difficult. As a result, 
clinicians largely rely on their own clinical experience and 
on the expert opinion-based literature on management of 
patients with esophageal perforation [5, 12, 13, 22, 23].
Risk factors for mortality in patients with esophageal per-
foration have been previously assessed and include age, co-
morbidity (mainly cardiovascular, liver and renal disease), 
etiology (i.e., BS) and initial treatment with endoscopic 
interventions [6]. Some studies have suggested that TOD is 
also a risk factor for adverse clinical outcome, but so far no 
studies clearly have demonstrated an independent associa-
tion in patients with esophageal perforation [5, 9–13, 24]. 
This may be explained by at least two factors. First, as men-
tioned above, studies generally consist of small case series 
(range 27–119 patients [5, 9–13, 24]) from one center, which 
allows authors to perform only univariable analyses without 
accounting for type of perforation and treatment strategy. 
Second, treatment options selected for the management of 
esophageal perforation in these studies vary considerably 
within and between studies, which also causes heterogeneity 
(Supplementary Table 5) [25, 26]. In an effort to overcome 
Table 5  Multi-level multivariable logistic regression analysis of risk factors for overall mortality during follow-up of patients with IEP or BS
Bold p-values indicate that differences between the groups were statistically significant
−Could not be estimated due to limited data
n, number of patients, IEP iatrogenic esophageal perforation, BS Boerhaave’s syndrome, OR odds ratio, CI confidence interval, ICU intensive 
care unit
*Analysis is adjusted for age, gender, location of perforation, initial treatment modality and center of treatment
IEP (n = 576) Adjusted* BS (n = 384) Adjusted*
Risk factor Yes No p OR 95%CI p Yes No p OR 95%CI p
Overall mortality
 Age ≥ 70 35 (15%) 20 (6%) < 0.001 2.9 1.5–5.7 0.002 41 (30%) 24 (10%) < 0.001 5.9 3.0–11.5 < 0.001
 Male gender 35 (11%) 20 (8%) 0.358 1.5 0.8–2.7 0.197 52 (18%) 13 (13%) 0.223 0.5 0.3–1.1 0.107
 Proximal location 23 (8%) 32 (12%) 0.132 1.8 1.0–3.3 0.064 13 (20%) 51 (16%) 0.488 1.0 0.4–2.5 0.975
 Initial treatment
 Surgery only 28 (10%) 27 (9%) 0.511 0.3 0.1–0.9 0.026 32 (14%) 33 (22%) 0.043 1.2 0.4–3.7 0.811
 Endoscopy only 10 (7%) 45 (10%) 0.278 0.2 0.1–0.7 0.011 8 (15%) 57 (17%) 0.750 0.9 0.2–3.5 0.913
 Conservative only 10 (7%) 45 (10%) 0.291 0.3 0.1–0.9 0.028 20 (36%) 45 (14%) < 0.001 3.4 0.9–12.3 0.060
 Surgery and endoscopy 7 (23%) 48 (9%) 0.008 – – – 5 (12%) 60 (18%) 0.325 – – –
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these shortcomings, we pooled individual data from almost 
a thousand patients and performed multivariable regression 
analysis. This allowed to stratify clinical outcome by type of 
perforation and also to adjust for confounding.
In the present study, we hypothesized that early TOD 
(within 12–24 h) improves overall survival in patients with 
IEP and BS. To test this hypothesis, we adjusted for several 
factors (e.g., center of treatment, type of initial manage-
ment) that could influence clinical outcome. Despite this, 
we only found a trend favoring early diagnosis when study-
ing the association between TOD and overall mortality in 
individual causes of benign esophageal perforation (IEP: 
p = 0.067 and BS: p = 0.104). The absence of this associa-
tion is likely explained by a limited statistical power, but the 
combined results of IEP and BS showed a much stronger 
benefit with regard to overall outcome measures. Nonethe-
less, this pooled analysis should be interpreted with caution 
as the results cannot be directly translated to clinical practice 
as we also showed that IEP and BS are clinically different 
conditions. Furthermore, it should be kept in mind, that for 
a complex multifactorial clinical problem like esophageal 
perforation, other possible prognostic factors, for example 
admission or transfer to a high volume center with experi-
ence in multidisciplinary care may adversely impact timely 
management but also reduce the mortality risk [27]. When 
establishing TOD as an independent risk factor for mortality 
in a multivariable analysis, adjustment for center of treat-
ment or other factors will likely still confound the outcome.
Nevertheless, the question remains how a diagnosis of 
esophageal perforation can be accelerated. In patients with 
IEP, careful monitoring for signs of esophageal perforation 
may be helpful as it particularly may occur in therapeutic 
upper endoscopic gastrointestinal procedures [1]. Although 
monitoring of patients for adverse events after therapeutic 
interventions of the upper gastrointestinal tract is advised 
by the European Society for Gastrointestinal Endoscopy 
(ESGE) [28], IEP is still frequently missed during the first 
24 h after endoscopy. This is supported by our observation 
that IEP was diagnosed after 12 h in one-third (33%) and 
after 24 h in one-fifth (21%) of patients. Close observation 
for at least 12 h after therapeutic esophageal procedures is 
therefore strongly recommended [28–30]. In contrast to IEP, 
early diagnosis of BS likely will remain a major challenge 
in clinical practice as it usually occurs in an out-of-hospital 
setting and often mimics various other acute conditions (e.g., 
ischemic cardiac disease) [31].
The main strength of this study is that we were able to use 
original source data. First, participating authors reviewed 
and shared their original data according to our pre-specified 
study definitions. We were able to set up a database with 
uniformly defined parameters without being restricted by 
divergent definitions used in the original studies. Further-
more, this systematic approach allowed obtaining additional 
unpublished data that were required for analysis of study 
endpoints.
Second, the data set allowed performing a multivariable 
analysis while correcting for the established confounders 
age and therapeutic approach. We further included poten-
tial confounders including gender, esophageal location, 
initial conservative treatment and type of treatment center. 
Accounting for therapeutic approach seems also important. 
For example, patients treated conservatively either may have 
minor esophageal injury or, conversely, were in a poor medi-
cal condition and unfit for surgical or endoscopic interven-
tions, likely resulting in death shortly after presentation [32].
There are also some limitations that should be recognized 
when interpreting the findings of this study. First, data on 
TOD were missing in a considerable number of patients 
(30%). Second, after critical appraisal, we estimated that the 
included studies had a high risk of bias due to their observa-
tional design. The relative rarity and various clinical pres-
entations of esophageal perforation in daily clinical practice 
likely explains the lack of published prospective and ran-
domized controlled trials. Moreover, randomizing patients 
in the acute setting is challenging [33]. Even by adjusting 
for important confounders, limitations in our retrospective 
data set did not allow to adjust for disease severity and co-
morbidity of patients. We therefore recommend initiating 
nation-wide prospective registries that could generate high-
level evidence on clinical management of esophageal perfo-
ration, preferably stratified by type of perforation. In addi-
tion, future research should focus on the multidimensional 
aspect of management of esophageal perforation rather than 
individual factors such as a particular treatment modality.
In conclusion, this IPD meta-analysis suggests that early 
diagnosis within 12 to 24 h after onset was associated with 
improved clinical outcome compared with a late diagnosis in 
patients with IEP and BS. Our findings confirm current opin-
ion that these types of esophageal perforation are clinical 
emergencies that should be recognized as soon as possible.
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